Sustained Intraocular Pressure Elevation After Intravitreal Injection of Bevacizumab and Ranibizumab Associated with Trabeculitis by Sniegowski, Matthew et al.
28  The Open Ophthalmology Journal, 2010, 4, 28-29   
 
  1874-3641/10  2010 Bentham Open 
Open Access 
Sustained Intraocular Pressure Elevation After Intravitreal Injection of 
Bevacizumab and Ranibizumab Associated with Trabeculitis 
Matthew Sniegowski, Naresh Mandava and Malik Y. Kahook
* 
Rocky Mountain Lions Eye Institute, Department of Ophthalmology, University of Colorado Denver, Aurora, CO 80045, 
USA 
Abstract: Anti-vascular endothelial growth factor agents are frequently used to treat a variety of ocular neovascular 
diseases. While agents like bevacizumab and ranibizumab appear to be safe and effective, there have been reports of 
severe intraocular inflammation as well as sustained elevation of intraocular pressure (IOP) after single or multiple 
intravitreal injections of these protein-based therapeutics. The true mechanism leading to inflammation and/or sustained 
spikes in IOP remains unknown. We report a patient with sustained IOP elevation and kerato-precipitates on the 
trabecular meshwork after multiple injections of both bevacizumab and ranibizumab. We propose that monomer 
antibodies, aggregated proteins, or other high molecular weight molecules might lead to inflammation in the trabecular 
meshwork and subsequent elevation in IOP. 
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INTRODUCTION 
  Intravitreal injections of anti-vascular endothelial growth 
factor (VEGF) agents are commonly used to treat a variety 
of retinal and choroidal neovascular diseases. Intra-ocular 
pressure (IOP) is known to be elevated in the period 
immediately following an intravitreal injection; however, it 
was thought that these elevations were transient with a return 
of IOP to near baseline levels after thirty minutes [1-3]. 
Recently, an association between intravitreal anti-VEGF 
injections and sustained IOP elevations has been made [4-6].
 
Previous reports suggest that a likely mechanism for the 
prolonged increase in IOP may result from trabecular 
meshwork blockage due to the large size of bevacizumab 
(molecular weight = 149 kD) [4-6]. We present a case of 
elevated IOP in the setting of a unilateral trabeculitis after 
anti-VEGF therapy. We propose that an alternative theory 
for this observed phenomenon is that protein aggregates or 
other contaminants within the injected fluid may induce an 
immunologic response with subclinical inflammation and 
secondary IOP elevation [7].
 
CASE REPORT 
  A 66 year old male with exudative age-related macular 
degeneration (AMD) in his right eye and non-exudative 
AMD in his left eye was referred to our tertiary care center 
for treatment. The patient’s ocular history prior to being seen 
by our retina service was significant for bilateral 
pseudophakia followed by subsequent laser capsulotomies 
for bilateral posterior capsular opacification. Over the course 
of his care, he received three injections of bevacizumab 
(Avastin, Genentech, Inc., San Francisco, CA) and eighteen  
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injections of ranibizumab (Lucentis, Genentech, Inc., San 
Francisco, CA). Previous IOP levels in both eyes were stable 
in the mid-teens for two years prior to presenting to our 
clinic. The patient was followed over the next four years and 
received injections of either ranibizumab or bevacizumab in 
the right eye at intervals between 4 and 12 weeks. He was 
noted to have occasional elevations in IOP up to 20-21 mm 
Hg, in his right eye, over the first three years of treatment. 
The left eye IOP remained stable in the low to mid teens. 
After 12 intravitreal injections, the patient began to have 
fluctuations in right eye IOP ranging from 22-26 mm Hg. 
Upon examination twelve weeks after the eighteenth 
injection of ranibizumab, the patient was found to have an 
IOP of 32 mm Hg on the right side. He was started on 
brimonidine three times a day and referred to the glaucoma 
service the next day. Upon follow-up examination, the 
patient’s IOP was found to have decreased to 22 mm Hg and 
gonioscopic examination demonstrated what appeared to be 
kerato-precipitates on the trabecular meshwork (Figs. 1A, 
B). Brimonidine was stopped and the patient was started on 
prednisolone acetate 1% four times a day. The IOP 
decreased to 18 mm Hg three days later. While the anterior 
chamber was initially devoid of any inflammatory cells, 
slight cell and flare appeared on subsequent follow up 
examinations and then faded with the continued topical 
steroid therapy. Subsequent work-up for uveitis was 
negative. The IOP remained low over subsequent visits 
without use of topical pressure lowering drops and the 
kerato-precipitates resolved. The patient has been weaned off 
of the steroid drops without recurrence of inflammation or 
IOP spikes and we have avoided further use of anti-VEGF 
agents. 
DISCUSSION 
  With widespread use of intravitreal anti-VEGF therapy for a 
variety of ophthalmic diseases, cases of sustained elevation of 
IOP are beginning to emerge [4-6]. Both bevacizumab, a 149 Bevacizumab and Ranibizumab Associated with Trabeculitis  The Open Ophthalmology Journal, 2010, Volume 4    29 
kDa full-length antibody and, ranibizumab, a 48 kDa antibody 
fragment, are known to diffuse into the anterior chamber, where 
they persist for some time prior to exiting through the aqueous 
outflow system [8, 9]. Previously published reports, have 
suggested that the increased IOP following intravitreal 
bevacizumab may be, at least in part, secondary to a physical 
blockage of the outflow system by the anti-VEGF agents. 
Blockade of the trabecular meshwork outflow system from 
bevacizumab monomers and fab fragments of ranibizumab is 
unlikely to be the true reason behind this phenomenon due to 
the low incidence of reported spikes in IOP. It may be that 
protein-based therapeutics can occasionally be altered in some 
way to cause protein aggregation with subsequent blockade of 
aqueous egress. Another possibility is that contaminants, such 
as silicone oil from the syringe barrel or rubber stopper, could 
lead to obstruction of the outflow system [10]. These theories 
remain speculative at this point. 
 
Fig. (1A). Gonioscopic view of the uninvolved left eye showing 
normal drainage angle anatomy. 
 
Fig. (1B). Gonioscopic view of the right eye revealing a hazy view 
with white deposits (arrow) over the trabecular meshwork. 
  Significant inflammatory reactions, even after previous 
uneventful injections are known to occur following the 
intravitreal injections of bevacizumab [11]. It is also well known 
and characterized that aggregated proteins, especially multimers 
in excess of 100kD, induce a much more vigorous immunologic 
response than their non-aggregated counterparts. Even small 
amounts of foreign protein aggregates induce a much stronger 
immune response than larger amounts of endogenous protein 
[7]. The intraocular injection of foreign proteins may lead to an 
inflammatory reaction and subsequent trabeculitis and IOP 
elevation in some patients. This phenomenon, along with other 
possible coexisting factors such as mechanical blockage of the 
outflow system, suggests that patients should be followed 
closely for spikes in IOP that can lead to optic nerve damage. 
While the present case may illustrate a potential link between 
anti-VEGF injections and subsequent inflammation with IOP 
elevation, there remains no proof of definitive direct causal 
relationship for the observed phenomenon. In the case we 
report, the patient maintained a decrease in IOP after 
discontinuation of topical aqueous suppressants and initiation of 
topical steroid therapy. This may have implications for future 
antibody based therapeutics for ophthalmic diseases. More 
research is needed in this area to fully elucidate the mechanism 
of increased intraocular pressure following intravitreal 
bevacizumab and ranibizumab. 
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